Rocaglamide Derivatives for eIF4A-Driven Translation Blockade in MPNSTs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas with high recurrence and metastasis rates, and current treatments are refractory, offering only modest and transient responses, necessitating a more effective therapeutic approach.
Innovation Solution
Development of rocaglamide derivatives, such as didesmethylrocaglamide (DDR) and rocaglamide (Roc), which target the eukaryotic initiation factor 4A (eIF4A) to inhibit translation initiation, thereby arresting MPNST cells at G2/M, inducing apoptosis, and suppressing oncogenic kinases like AKT and ERK1/2, with improved drug-like properties and oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (statins, farnesyl transferase inhibitors, RTK inhibitors, mTOR inhibitors) are used to target Ras signaling pathways in MPNSTs, then some antitumor activity is achieved, but survival remains poor and responses are modest and transient
Solution Approach 1:
The patent changes the target parameter from downstream effectors (RTKs, mTOR, Raf) to the upstream translation initiation complex (eIF4F). By targeting eIF4A, the mechanism of action is fundamentally altered, leading to more durable responses. The compound silvestrol and its derivatives inhibit eIF4A directly, preventing translation initiation and causing sustained cell cycle arrest and apoptosis, thereby extending the duration of response compared to transient responses seen with pathway inhibitors.
Solution Approach 2:
The patent extracts the critical vulnerability of MPNSTs from the complex Ras signaling network and identifies the translation initiation complex (eIF4F) as the key target. By isolating this specific target, the therapy achieves more reliable and durable effects. The extraction of eIF4A inhibition from the broader Ras pathway targeting approach allows for more precise and sustained interruption of tumor growth signals.
2Reliability
If silvestrol is used to inhibit eIF4A and suppress MPNST growth, then potent antitumor activity is achieved, but oral bioavailability is poor due to MDR1 efflux
Solution Approach 1:
The patent modifies the chemical structure of silvestrol by changing parameters at specific positions (C-6 and C-8b) to alter pharmacokinetic properties. The derivatives have modified substituent groups that reduce recognition by the MDR1 efflux pump while maintaining eIF4A binding affinity. This structural parameter change enables improved oral bioavailability without sacrificing antitumor activity.
Solution Approach 2:
The patent converts the harmful effect of MDR1 efflux (which originally reduced bioavailability) into a benefit by designing compounds that specifically evade MDR1 recognition. The structural modifications create molecules that are not substrates for MDR1, thereby transforming the previously problematic efflux mechanism into a non-issue, allowing for effective oral administration.
3Reliability
If multiple targeted drugs are combined to address multiple critical pathways in MPNSTs, then cure likelihood increases, but treatment complexity and toxicity increase
Solution Approach 1:
The patent extracts the primary driver of MPNST growth from the complex network of Ras downstream pathways and identifies translation initiation (eIF4F) as the master regulator. By targeting this single upstream node, the therapy simplifies the treatment approach compared to combining multiple pathway inhibitors. The extraction of eIF4A as the critical target allows for monotherapy that addresses multiple downstream effects simultaneously.
Solution Approach 2:
The patent achieves multi-functionality by targeting a single upstream regulator (eIF4A) that controls multiple downstream processes including protein translation, cell cycle progression, and apoptosis. This single target inhibition simultaneously affects multiple critical pathways (PI3K-AKT-mTOR, Raf-MEK-ERK), providing broad antitumor activity without requiring combination therapy for each pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Rocaglamides effectively inhibit MPNST growth, induce apoptosis, and suppress multiple sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma, with reduced pulmonary toxicity and enhanced bioavailability, suggesting them as viable treatments for these cancers.
Implementation Method 1
target the eukaryotic initiation factor 4A (eIF4A) to inhibit translation initiation, thereby arresting MPNST cells at G2/M
Implementation Method 2
inducing cleavage of caspases and poly(ADP-ribose) polymerase, and elevated the levels of γH2A.X
Implementation Method 3
suppressing oncogenic kinases like AKT and ERK1/2
Data Source
AI summary
A method of treating nervous system cancer or soft-tissue sarcoma in a subject is described. The method includes administering a therapeutically effective amount of a compound according to formula I to a subject in need thereof:wherein R1 is selected from the group consisting of —OH, —OAc, —OCHO, ═O, and ═NOH; R2 is selected from the group consisting of —CON(CH3)2, —CONHCH3, —CONH2, —COOCH3, —COOH, and —H, R3 is selected from the group consisting of —H, —OH, and —OCH3, and R4 is selected from the group consisting of —OH, —OCH3, —OCH2CH3.